Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors.
Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer.
Gain key clinical insights fast, with this short slideset from CCO on the optimal use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.
Download these slides from a live Webinar to gain expert insight on the new and emerging data on the optimal use of CDK4/6 and PI3K inhibitors for patients with HR+/HER2 breast cancer.
In an engaging discussion led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Dr. Sara Hurvitz, MD, FACP, share how they currently use CDK4/6 inhibitors for their patients with metastatic HR-positive/HER2-negative breast cancer, the potential clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021, and strategies for counseling patients receiving CDK4/6 inhibitors.
Downloadable slides accompanying a podcast led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, about how they use CDK4/6 inhibitors for patients with HR-positive/HER2-negative breast cancer, including key studies on CDK4/6 inhibitors from ASCO 2021.
Faculty review recent clinical trial data and provide their insights on the use of CDK4/6 inhibitors and PI3K inhibitors for HR+/HER2- breast cancer.
Hear expert perspective from Laura M. Spring, MD, on how she will integrate adjuvant abemaciclib into clinical practice.
Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with oral targeted therapy for HR-positive, HER2-negative breast cancer from 5 experts.
For further information concerning Lilly grant funding,